ArticleBlood advances2020

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

Reid W Merryman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.